IL2 and inflammatory bowel disease: Administration of anti-CD44 antibodies inhibited inflammation in mouse models of inflammatory bowel disease, collagen- and proteoglycan-induced arthritis, cutaneous inflammation, and IL-2-induced vascular leak [70].